Skip to main content

Table 1 Summary of radiochemical characteristics and bioactivities of scFvD2B after labeling with 124I

From: Anti-PSMA 124I-scFvD2B as a new immuno-PET tool for prostate cancer: preclinical proof of principle

Radiolabeling

experiments

1

2

3

4

% Efficiency

91

94

94

98

% Radiochemical purity

98

100

100

100

% Immunoreactivity on

 PSMA positive cells

  PC3-PIP

91

82

82

88

  LNCaP

84

82

75

80

 PSMA negative cells

  PC3

1.3

1.1

2.0

3.2

  A431

0.9

0.2

0.4

0.4

Specific Activity (MBq/mg)

166.5

196.1

381.1

432.9